Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 1/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.32 |
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.32 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.31 |
| ▸ | NAMPT | P43490 | 1/20 | 0.31 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.30 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.30 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.30 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.30 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.30 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2494384 | 0.67 | NUDT1 (0.40) | CYP11B1CYP11B2SLC22A12NUDT1NAMPT | |
| SCHEMBL2492073 | 0.60 | NUDT1 (0.43) | CYP11B1CYP11B2SLC22A12NUDT1NAMPT | |
| SCHEMBL2063380 | 0.58 | KCNA5 (0.44) | SLC22A12NUDT1KCNA5 | |
| SCHEMBL2494649 | 0.58 | NUDT1 (0.41) | CYP11B1CYP11B2SLC22A12NUDT1NAMPT | |
| SCHEMBL17591685 | 0.57 | CFTR (0.52) | OPRM1OPRD1KCNA5 | |
| SCHEMBL23970127 | 0.57 | CFTR (0.57) | OPRM1OPRD1KCNA5 | |
| SCHEMBL27610248 | 0.56 | NOTUM (0.49) | SLC22A12NUDT1NOTUM | |
| SCHEMBL4546585 | 0.56 | NOTUM (0.51) | NUDT1NOTUM | |
| SCHEMBL24597109 | 0.54 | SLC22A12 (0.44) | CYP11B1CYP11B2SLC22A12NUDT1NOTUM | |
| SCHEMBL29598502 | 0.53 | NOTUM (0.56) | CYP11B1CYP11B2NOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8030332-B2 | Potassium channel inhibitors | MERCK SHARP & DOHME CORP. (US) | 2011-10-04 | — | — | US | disclosed |
| US-20090069312-A1 | Potassium Channel Inhibitors | MERCK SHARP & DOHME CORP. | 2009-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069312-A1 | Potassium Channel Inhibitors | KCNJ2, KCNH2, KCNH3 | CYP11B1 3175/4885CYP11B2 3141/4885SLC22A12 1458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.